Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

396
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
396
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

579
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
579
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

345
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Good clinical trial funding practices: how can public funders reduce the risk of trial failure and improve health impact?

Trials·2026
Same author

Cost-effectiveness of maternal vaccine and/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants.

NPJ vaccines·2026
Same author

An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Unmet health-related needs in patients with Crohn's disease in Belgium: a mixed-methods study.

Archives of public health = Archives belges de sante publique·2025
Same author

The validation of the Needs Examination, Evaluation, and Dissemination assessment framework within the European Union: a modified Delphi study.

European journal of public health·2025
Same author

Identification of health-related needs: The needs examination, evaluation and dissemination (NEED) assessment framework.

Health policy (Amsterdam, Netherlands)·2025

Related Experiment Video

Updated: Apr 15, 2026

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients
11:05

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

Published on: February 6, 2021

17.6K

Belgian guidelines for economic evaluations: second edition.

Nancy Thiry1, Mattias Neyt1, Stefaan Van De Sande1

  • 1Belgian Health Care Knowledge Centre (KCE),Nancy.Thiry@kce.fgov.be.

International Journal of Technology Assessment in Health Care
|March 31, 2015
PubMed
Summary
This summary is machine-generated.

Updated methodological guidelines for healthcare economic evaluations in Belgium are presented. These guidelines aim to enhance the quality, transparency, and uniformity of economic evaluations for drugs, medical devices, and other health interventions.

Keywords:
Reimbursement

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.4K
A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible
10:42

A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible

Published on: January 28, 2020

7.2K

Related Experiment Videos

Last Updated: Apr 15, 2026

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients
11:05

SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients

Published on: February 6, 2021

17.6K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.4K
A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible
10:42

A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible

Published on: January 28, 2020

7.2K

Area of Science:

  • Health Economics
  • Health Technology Assessment
  • Methodology

Background:

  • Previous guidelines for economic evaluations in Belgium required updating.
  • User feedback and expert experience informed the revision process.

Purpose of the Study:

  • To present updated methodological guidelines for economic evaluations of healthcare interventions in Belgium.
  • To establish a reference case for minimal requirements in Belgian economic evaluations.

Main Methods:

  • Revision by Belgian health economists based on user feedback and experience.
  • Discussion with a multidisciplinary team including industry and reimbursement assessors.
  • Validation by external experts not involved in the revision process.

Main Results:

  • Comprehensive methodological guidance is provided for key components of economic evaluations.
  • Specific guidance covers literature review, perspective, target population, comparators, cost calculation, outcome valuation, time horizon, modeling, uncertainty, and discounting.
  • A reference case is proposed as a minimum standard.

Conclusions:

  • The updated guidelines will improve the methodological quality, transparency, and uniformity of economic evaluations in Belgium.
  • These guidelines will support researchers and assessors involved in economic evaluations.